Natco Pharma has reported results for fourth quarter and year ended March 31, 2017.
The company has reported has posted over 2-fold jump in its net profit after tax at Rs 177.30 crore for the quarter ended March 31, 2017 as compared to Rs 69 crore for the same quarter in the previous year. Total income of the company increased by 41.09% at Rs 554.50 crore for quarter under review as compared to Rs 393 crore for the quarter ended March 31, 2016.
On consolidated basis, the company has posted around 3-fold jump in its net profit at Rs 176.40 crore for the quarter ended March 31, 2017 as compared to Rs 63 crore for the same quarter in the previous year. Total income of the company increased by 46.20% at Rs 577.20 crore for quarter under review as compared to Rs 394.80 crore for the same quarter ended previous year.
For the year ended March 31, 2017, the company has posted around 3-fold jump in its net profit at Rs 494.80 crore as compared to Rs 176.50 crore in FY16. Total income of company increased by 88.04% at Rs 2016 crore for year under review as compared to Rs 1072.10 crore for the year ended March 31, 2016.
For the year ended March 31, 2017, on the consolidated basis, the company has posted over 3-fold jump in its net profit at Rs 484.90 crore as compared to Rs 155.80 crore in the previous year. Total income of the company increased by 90.78% at Rs 2078.90 crore for year under review as compared to Rs 1089.70 crore for the year ended March 31, 2016.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: